InsidersTradesSigma
IRIDEX CORP Stock: price and directors' dealings · United States · SEC (Form 4)
Track the IRIDEX CORP share price and the full insider trade history of the company, a listed equity based in United States. Shares trade on US US, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, IRIDEX CORP has recorded 94 reports. Market capitalisation: €19.5m. The latest transaction was disclosed on 8 July 2026 (J). Among the most active insiders: Mercer Patrick. Every trade is accessible without an account.
94
Insider Decl.
0
Thresholds
€126,569
29 ops.
Buy Volume
·
0 ops.
Sell Volume
48Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 24,086 of 25,837 companies
18.3
score / 100
Value13
Quality24
FCF yld-12%
Earn yld-23%
EV/EBITDA·
ROE-57%
Gross mgn37%
Net mgn-8.4%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 8 July 2026
Declarations94 total
111,997 sharesCommon StockSEC:0002064835-26-000071:0
2,691 sharesCommon StockSEC:0001193125-26-273105:0
975 sharesCommon StockSEC:0001193125-26-270572:0
Ideal exit: 9 Mar 2027 (T+270)
2,400 sharesCommon StockSEC:0001193125-26-263083:0
Ideal exit: 5 Mar 2027 (T+270)
2,521 shares@ US$1.150.013% mcap35.4% of flowCommon StockSEC:0001193125-26-260846:0
Ideal exit: 2 Mar 2027 (T+270)
87,949 sharesCommon StockSEC:0002097627-26-000013:0
100 shares@ US$1.012.0% of flowCommon StockSEC:0000950170-25-076452:0
Ideal exit: 16 Feb 2026 (T+270)
15,000 shares@ US$1.100460.9% of flowCommon StockSEC:0000950170-25-073287:0
Ideal exit: 8 Feb 2026 (T+270)
460 shares@ US$1.109.9% of flowCommon StockSEC:0000950170-25-072860:0
Ideal exit: 8 Feb 2026 (T+270)
100 shares@ US$1.152.3% of flowCommon StockSEC:0000950170-25-070561:0
Ideal exit: 7 Feb 2026 (T+270)
100 shares@ US$1.162.3% of flowCommon StockSEC:0000950170-25-069531:0
Ideal exit: 6 Feb 2026 (T+270)
100 shares@ US$1.152.2% of flowCommon StockSEC:0000950170-25-068162:0
Ideal exit: 3 Feb 2026 (T+270)
100 shares@ US$1.152.2% of flowCommon StockSEC:0000950170-25-067265:0
Ideal exit: 2 Feb 2026 (T+270)
193 shares@ US$1.154.3% of flowCommon StockSEC:0000950170-25-066107:0
Ideal exit: 1 Feb 2026 (T+270)
100 shares@ US$1.192.3% of flowCommon StockSEC:0000950170-25-064704:0
Ideal exit: 31 Jan 2026 (T+270)
100 shares@ US$1.202.3% of flowCommon StockSEC:0000950170-25-063773:0
Ideal exit: 30 Jan 2026 (T+270)
290 shares@ US$1.241.3% of flowCommon StockSEC:0000950170-25-060953:0
Ideal exit: 23 Jan 2026 (T+270)
500 shares@ US$1.3012.5% of flowCommon StockSEC:0000950170-25-060479:0
Ideal exit: 24 Jan 2026 (T+270)
46 shares@ US$1.150.1% of flowCommon StockSEC:0000950170-25-059404:0
Ideal exit: 19 Jan 2026 (T+270)
625 shares@ US$1.2214.7% of flowCommon StockSEC:0000950170-25-059458:0
Ideal exit: 23 Jan 2026 (T+270)
21,457 shares@ US$1.2024.7% of flowCommon StockSEC:0000950170-25-058434:0
Ideal exit: 19 Jan 2026 (T+270)
975 shares@ US$1.1822.2% of flowCommon StockSEC:0000950170-25-058622:0
Ideal exit: 20 Jan 2026 (T+270)
500 shares@ US$1.1110.7% of flowCommon StockSEC:0000950170-25-058218:0
Ideal exit: 18 Jan 2026 (T+270)
25,900 shares@ US$1.216228.7% of flowCommon StockSEC:0000950170-25-058084:0
Ideal exit: 18 Jan 2026 (T+270)
10,000 shares@ US$1.05437.8% of flowCommon StockSEC:0000950170-25-057602:0
Ideal exit: 16 Jan 2026 (T+270)
25 of 94 declarations
About IRIDEX CORP
IRIDEX Corporation (ticker: IRIX) is a U.S.-based ophthalmic medical technology company listed on Nasdaq in the United States, part of the NYSE/NASDAQ universe followed by global equity investors. The company was founded in 1989 as IRIS Medical Instruments, Inc., later renamed IRIDEX Corporation in 1996, and has long been associated with Silicon Valley. Its executive offices remain in Mountain View, California, although in February 2026 the company announced plans to relocate its headquarters to San Jose to lower operating costs. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001006045/000119312526140194/irix-20260103.htm)) IRIDEX focuses on the development, manufacturing, and commercialization of therapeutic laser systems, delivery devices, and single-use consumable instrumentation for ophthalmology. Its core addressable markets are glaucoma and retinal diseases, including diabetic macular edema (DME). Key product families include the Cyclo G6® laser system for glaucoma, the Iridex 532® and Iridex 577® lasers, and the proprietary MicroPulse® technology, which the company positions as a differentiated laser treatment designed to be safer and more tissue-sparing than conventional continuous-wave laser approaches. Consumable probes and delivery accessories are an important part of the product stack and help support recurring revenue. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001006045/000119312526140194/irix-20260103.htm)) From a competitive standpoint, IRIDEX is a niche specialist rather than a broad-line ophthalmic equipment conglomerate. Its investment case rests on clinical differentiation, installed base, and scientific validation, particularly around MicroPulse applications in glaucoma management and retinal therapy. That specialization can be an advantage in targeted indications where surgeons value precision, safety, and repeatability, but it also means the company operates in a competitive, innovation-driven market where reimbursement, adoption rates, and physician preference matter materially. ([iridex.gcs-web.com](https://iridex.gcs-web.com/news-releases/news-release-details/iridex-reports-fourth-quarter-and-full-year-2025-financial?utm_source=openai)) Geographically, the company sells primarily in the United States through a direct sales force, while international business is handled mainly through independent distributors. Its 2025 Form 10-K states that products were sold in the U.S. and Germany directly, and in other international markets via Topcon Corporation and additional distributors, including Italy, the U.K. (glaucoma), India, and smaller markets. The company also stated that its products are sold into more than 100 countries. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001006045/000119312526140194/irix-20260103.htm)) Recent company developments have been noteworthy. In March 2026, IRIDEX reported full-year 2025 revenue of $52.7 million versus $48.7 million in 2024, while narrowing net loss to $4.4 million from $8.9 million. In 2025 and early 2026, it highlighted clinical publications supporting MicroPulse, launched a U.K. study in diabetic macular edema, appointed Patrick Mercer as CEO in October 2024, announced a strategic investment in March 2025, and disclosed its headquarters relocation plan in February 2026. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001006045/000119312526140194/irix-20260103.htm))
